Imperative Trial

Download the product specs

Important safety information

Study Objective

To assess the safety and efficacy of the Zoom System, including aspiration with 0.088” ID catheters, within 8 hours of symptom onset.

Prospective, Consent Before Groin Puncture

26 Hospitals with Patients Enrolled

211 Patients with Concomitant Aspiration1

0.088” Aspiration Indication as part of the Zoom System

Trial Results

19

Minutes

Median groin puncture to mTICI ≥ 2B2

Fastest time to reperfusion of major prospective MT trials3

4.7%

Rescue device rate

Rescue device rate to achieve 91%
final reperfusion (mTICI2b+)2, 4

Lowest rescue device rate of major prospective MT trials5

26%

Type 3 arches6

Encompassed significantly more type 3 arches than real-world anatomy7

Excellent Safety Profile

0.5%

Serious vessel injury2

0.9%

sICH2

M2 Cohort Results8

The Imperative Trial has shown excellent results, including
unparalleled safety in M2 occlusions.

69

Age, median

13

Baseline NIHSS, median

88%

Core-lab final TICI ≥ 2B

55%

mRS 0-1

1.5%

sICH

The Imperative Trial has shown excellent results, including
unparalleled safety in M2 occlusions.

Skull with blood vessels

Read the M2 Subgroup Analysis Published in the Journal of Neurointerventional Surgery

Published Data

Note: individual trials are not directly comparable and data is presented for observational purposes only.

1 Total study population = 260 patients. Results presented include concomitant aspiration cohort only. n=211
2 Zoom System IFU (LBL002069.A), n=211
3 Major MT trials with reperfusion times reported: ARISE II, TIGER, PROST, PENUMBRA 3D, ASTER, COMPASS, DEFUSE 3, DAWN
4 IMPERATIVE Trial data cohort analysis, n=211
5 Major MT trials with rescue rates reported: Compared to: ASTER, COMPASS, ARISE II, TIGER, PROST
6 Mokin et al. INR 2025
7 Mokin et al. Neuroradiology 2021
8 Mascitelli et al. JNIS 2025